Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Ocular Therapeutix (NASDAQ: OCUL) has announced its participation at Clinical Trials at the Summit 2025, scheduled for June 21, 2025, in Las Vegas. The company will deliver multiple presentations focused on their OTX-TKI program, including Phase 1 study results of sustained-release axitinib hydrogel for wet AMD, updates on SOL-1 and SOL-R pivotal Phase 3 trials, and safety and efficacy data from the HELIOS Phase 1 study for diabetic retinopathy. Key company representatives, including CSO Sanjay Nayak and CDO Peter K. Kaiser, will participate in various sessions and panel discussions covering topics from clinical trial results to regulatory guidance and industry innovation. The presentations will showcase Ocular's developments in ophthalmology treatments and their potential impact on patient care.
Ocular Therapeutix (NASDAQ: OCUL) ha annunciato la sua partecipazione al Clinical Trials at the Summit 2025, previsto per il 21 giugno 2025 a Las Vegas. L'azienda presenterà diverse relazioni focalizzate sul programma OTX-TKI, inclusi i risultati dello studio di Fase 1 sull'idrogel a rilascio prolungato di axitinib per la degenerazione maculare umida (wet AMD), aggiornamenti sugli studi pivotali di Fase 3 SOL-1 e SOL-R, e dati di sicurezza ed efficacia dallo studio HELIOS di Fase 1 per la retinopatia diabetica. I principali rappresentanti dell'azienda, tra cui il CSO Sanjay Nayak e il CDO Peter K. Kaiser, parteciperanno a varie sessioni e tavole rotonde che affronteranno temi dai risultati clinici alle linee guida regolatorie e all'innovazione nel settore. Le presentazioni metteranno in luce gli sviluppi di Ocular nei trattamenti oftalmologici e il loro potenziale impatto sulla cura dei pazienti.
Ocular Therapeutix (NASDAQ: OCUL) ha anunciado su participación en Clinical Trials at the Summit 2025, programado para el 21 de junio de 2025 en Las Vegas. La compañía realizará varias presentaciones centradas en su programa OTX-TKI, incluyendo los resultados del estudio de Fase 1 del hidrogel de liberación sostenida de axitinib para la DMAE húmeda, actualizaciones sobre los ensayos pivotales de Fase 3 SOL-1 y SOL-R, y datos de seguridad y eficacia del estudio HELIOS de Fase 1 para la retinopatía diabética. Representantes clave de la empresa, como el CSO Sanjay Nayak y el CDO Peter K. Kaiser, participarán en diversas sesiones y paneles que cubrirán temas desde resultados de ensayos clínicos hasta guías regulatorias e innovación en la industria. Las presentaciones mostrarán los avances de Ocular en tratamientos oftalmológicos y su posible impacto en el cuidado de los pacientes.
Ocular Therapeutix(NASDAQ: OCUL)는 2025년 6월 21일 라스베이거스에서 열리는 Clinical Trials at the Summit 2025에 참여한다고 발표했습니다. 회사는 지속 방출형 악시티닙 하이드로겔을 이용한 습성 황반변성(wet AMD) 1상 연구 결과, SOL-1 및 SOL-R 3상 결정적 시험의 최신 정보, 당뇨병성 망막병증을 위한 HELIOS 1상 연구의 안전성과 효능 데이터를 포함한 OTX-TKI 프로그램 관련 여러 발표를 진행할 예정입니다. CSO Sanjay Nayak와 CDO Peter K. Kaiser를 포함한 주요 회사 대표들이 임상시험 결과, 규제 지침, 산업 혁신 등 다양한 세션과 패널 토론에 참여합니다. 이번 발표는 안과 치료 분야에서 Ocular의 개발 현황과 환자 치료에 미칠 잠재적 영향을 보여줄 것입니다.
Ocular Therapeutix (NASDAQ : OCUL) a annoncé sa participation au Clinical Trials at the Summit 2025, prévu le 21 juin 2025 à Las Vegas. La société présentera plusieurs communications axées sur son programme OTX-TKI, incluant les résultats de l'étude de phase 1 sur l'hydrogel à libération prolongée d'axitinib pour la DMLA humide, des mises à jour sur les essais pivots de phase 3 SOL-1 et SOL-R, ainsi que des données de sécurité et d'efficacité de l'étude HELIOS de phase 1 pour la rétinopathie diabétique. Des représentants clés de l'entreprise, dont le CSO Sanjay Nayak et le CDO Peter K. Kaiser, participeront à diverses sessions et tables rondes abordant des sujets allant des résultats des essais cliniques aux directives réglementaires et à l'innovation dans l'industrie. Ces présentations mettront en lumière les avancées d'Ocular dans les traitements ophtalmologiques et leur impact potentiel sur la prise en charge des patients.
Ocular Therapeutix (NASDAQ: OCUL) hat seine Teilnahme am Clinical Trials at the Summit 2025 angekündigt, das am 21. Juni 2025 in Las Vegas stattfindet. Das Unternehmen wird mehrere Präsentationen zu seinem OTX-TKI-Programm halten, darunter Ergebnisse der Phase-1-Studie zum langanhaltenden Axitinib-Hydrogel für feuchte AMD, Updates zu den entscheidenden Phase-3-Studien SOL-1 und SOL-R sowie Sicherheits- und Wirksamkeitsdaten aus der HELIOS Phase-1-Studie zur diabetischen Retinopathie. Wichtige Unternehmensvertreter, darunter CSO Sanjay Nayak und CDO Peter K. Kaiser, werden an verschiedenen Sitzungen und Podiumsdiskussionen teilnehmen, die Themen von klinischen Studienergebnissen über regulatorische Leitlinien bis hin zu Innovationen in der Branche abdecken. Die Präsentationen werden die Entwicklungen von Ocular in der ophthalmologischen Behandlung und deren potenzielle Auswirkungen auf die Patientenversorgung hervorheben.
Positive
- None.
Negative
- None.
BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las Vegas, NV.
Clinical Trials at the Summit (CTS) 2025 Presentation Details:
- Company Presentation: Ocular Therapeutix
Session: Diamond Sponsor Talks
Presentation Date/Time: Friday, June 20, 2025, 7:55 – 8:05 PM PT
Presenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer
- Presentation Title: Sustained-Release Axitinib Hydrogel (OTX-TKI) for Wet AMD: US Phase 1 Study Results
Session: Tyrosine Kinase Inhibitors in Clinical Trials
Presentation Date/Time: Saturday, June 21, 2025, 9:05 – 9:09 AM PT
Presenter: Patricio G. Schlottmann, MD
- Presentation Title: SOL-1 and SOL-R: Pivotal Phase 3 Trials Evaluating OTX-TKI for Wet AMD
Session: Tyrosine Kinase Inhibitors in Clinical Trials
Presentation Date/Time: Saturday, June 21, 2025, 9:09 – 9:13 AM PT
Presenter: Andrea Gibson, PhD, Senior Vice President, Medical Collaborations
- Presentation Title: Safety and Efficacy of OTX-TKI for Diabetic Retinopathy: HELIOS Phase 1 Study
Session: Tyrosine Kinase Inhibitors in Clinical Trials
Presentation Date/Time: Saturday, June 21, 2025, 9:25 – 9:29 AM PT
Presenter: Dilsher S. Dhoot, MD
- Panel Title: SOL Program Unpacked: Exploring OTX-TKI’s Potential with Trial Experts
Panel Date/Time: Saturday, June 21, 2025, 9:47 – 10:17 AM PT
Moderators: Anat Loewenstein, MD, MHA & Daniel F. Martin, MD
- Panel Title: Designing Pivotal Trials Aligned with Evolving Regulatory Guidance
Panel Date/Time: Saturday, June 21, 2025, 12:45 – 1:05 PM PT
Panelist: Peter K. Kaiser, MD, Chief Development Officer
- Panel Title: Shifting the Landscape: Can Innovation Truly Change the Paradigm?
Panel Date/Time: Saturday, June 21, 2025, 5:25 – 5:45 PM PT
Moderator: Peter K. Kaiser, MD, Chief Development Officer
Exact presentation times may be subject to change.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA™ (also known as OTX-TIC), which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
What will Ocular Therapeutix (OCUL) present at CTS 2025?
Ocular Therapeutix will present Phase 1 results for OTX-TKI in wet AMD, updates on SOL-1 and SOL-R Phase 3 trials, and HELIOS Phase 1 study results for diabetic retinopathy.
When and where is Ocular Therapeutix presenting at Clinical Trials at the Summit 2025?
The presentations will take place on June 21, 2025, in Las Vegas, with various sessions scheduled throughout the day from 9:05 AM to 5:45 PM PT.
Who are the key presenters from OCUL at the Clinical Trials Summit 2025?
Key presenters include Sanjay Nayak (CSO), Patricio Schlottmann (MD), Andrea Gibson (SVP Medical Collaborations), and Peter K. Kaiser (CDO).
What clinical trials will OCUL discuss at the summit?
OCUL will discuss the US Phase 1 study of OTX-TKI for wet AMD, SOL-1 and SOL-R Phase 3 trials, and the HELIOS Phase 1 study for diabetic retinopathy.
Ocular Therapeut
NASDAQ:OCUL
OCUL Rankings
OCUL Latest News
OCUL Stock Data
1.42B
151.09M
1.01%
85.07%
7.58%
Biotechnology
Pharmaceutical Preparations
United States
BEDFORD